A Phase 1/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients with Mature B-Cell Malignancies (BGB-11417-101) (NCT04277637)
BGB-11417-101
This trial is No longer recruiting
Registration number NCT04277637
Program & service
This trial is being run with the Cancer service, and as part of the Haematology program.
Trial phase
Phase 1
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Professor Constantine Tam
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTR